Atrial fibrillation (AF) continues to be a growing epidemic due to its increasing incidence, prevalence, and detrimental consequences. In 2017, the Global Burden of Disease study revealed 37.57 million prevalent cases and 3.05 million incident cases of AF globally, with 287,241 resulting in deaths [1]. Mortality in AF is largely attributed to co-morbidities such as cardiac failure but increasing evidence suggests that AF may be independently associated with ventricular arrhythmias (VAs) and sudden death, regardless of these conditions [2,3].
